[Featured Stock] Jinwon Life Sciences Begins Domestic Clinical Trials for COVID-19 Vaccine... 8.4 Billion Won Support from International Organization

[Asia Economy Reporter Hyungsoo Park] The stock price of Jinwon Life Science is on the rise. The news that the Korea Disease Control and Prevention Agency's National Institute of Health is collaborating with the international organization International Vaccine Institute (IVI) to advance domestic clinical trials of a COVID-19 vaccine candidate appears to have influenced the stock price.

As of 1:02 PM on the 16th, Jinwon Life Science is trading at 14,550 KRW, up 3.93% compared to the previous trading day.

The National Institute of Health announced that it will conduct domestic Phase 1 and 2 clinical trials using Inovio's COVID-19 vaccine candidate (INO-4800), which is currently undergoing clinical trials in the United States. The Coalition for Epidemic Preparedness Innovations (CEPI), an international public-private partnership, is providing funding of 6.9 million USD (approximately 8.4 billion KRW).

The National Institute of Health and the International Vaccine Institute will evaluate essential procedures for clinical trials such as safety and efficacy. DNA vaccines induce an immune response by administering genes that produce viral antigens into the human body. The National Institute of Health is collaborating with the Ministry of Food and Drug Safety from the planning review stage to expedite the clinical trial process.

This content was produced with the assistance of AI translation services.